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Abstract
Over a third of the US adult population has hypertriglyceridemia, resulting in an increased risk of
atherosclerosis, pancreatitis, and metabolic syndrome. Lipoprotein lipase (LPL)1, a dimeric
enzyme, is the main lipase responsible for TG clearance from the blood after food intake. LPL
requires an endoplasmic reticulum (ER)-resident, transmembrane protein known as lipase
maturation factor 1 (LMF1) for secretion and enzymatic activity. LMF1 is believed to act as a
client specific chaperone for dimeric lipases, but the precise mechanism by which LMF1 functions
is not understood. Here, we examine which domains of LMF1 contribute to dimeric lipase
maturation by assessing the function of truncation variants. N-terminal truncations of LMF1 show
that all the domains are necessary for LPL maturation. Fluorescence microscopy and protease
protection assays confirmed that these variants were properly oriented in the ER. We measured
cellular levels of LMF1 and found that it is expressed at low levels and each molecule of LMF1
promotes the maturation of 50 or more molecules of LPL. Thus we provide evidence for the
critical role of the N-terminus of LMF1 for the maturation of LPL and relevant ratio of chaperone
to substrate.
Introduction
LPL plays a critical and complex role in lipid metabolism. LPL hydrolyzes triglycerides
from two classes of circulating lipoproteins, very low-density lipoproteins and
chylomicrons, in order to distribute free fatty acids to peripheral tissues. Biochemical
deficiency of LPL activity is one well-established cause of hypertriglyceridemia, which is
associated with increased risk of atherosclerosis, acute pancreatitis, and presence of
metabolic syndrome [1]. Mutations in both LPL and its interacting partners can result in
biochemical deficiency of LPL activity. Here we investigate how one of these interacting
partners, LMF1, promotes LPL activity.
1Abbreviations: Lipoprotein Lipase (LPL), Lipase Maturation Factor 1 (LMF1), Endoplasmic Reticulum (ER), combined lipase
deficiency (cld)
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Deleterious mutations in the gene for LMF1 result in severe hypertriglyceridemia [2,3].
LMF1’s precise genetic location was recently discovered [2], but its role in promoting LPL
activity is well established. Mice with a recessive mutation on chromosome 17 were
severely deficient for LPL activity and hepatic lipase activity [4]. This mutation was termed
cld, for combined lipase deficiency [4]. Mice with homozygous disruptions in the LPL gene
had phenotypes that were indistinguishable from cld/cld mice (death within 48 hours of birth
with extreme hypertriglyceridemia [5]). However, the cld mutation did not affect the LPL
and hepatic lipase structural genes, as these genes mapped to different chromosomes [6].
Furthermore, the amount of LPL protein present in tissues was not reduced, but its activity
was [7]. LPL activity was reduced because the majority of the LPL was retained in the ER
as inactive aggregates in cld/cld cells [8]. Recently, the cld mutation was mapped to a gene
coding for an ER-resident, transmembrane protein, and renamed LMF1 [2]. Subsequently,
LMF1 was found to be important for the activity of a third dimeric lipase, endothelial lipase
[9].
Although LMF1 is vital for secretion of active, dimeric lipases, it is not clear how it
promotes the exit of dimeric lipases from the ER. It is therefore important to determine
which domains of LMF1 contribute to dimeric lipase maturation. Mapping studies of
LMF1’s domain architecture reveal that it has a total of five transmembrane domains with
its N-terminus in the cytosol and its C-terminus in the ER lumen [10]. The loops connecting
these transmembrane domains are labeled A-D and are diagramed in Figure 1A. Recent data
suggest that loop C and the C-terminus of LMF1 are important for dimeric lipase maturation
[10]. The importance of LMF1’s C-terminal, ER resident domain was established in studies
of the original cld mutation and in patients with LMF1 mutations. Two nonsense mutations
in the C-terminal ER domain of LMF1 (Y439X and W464X) resulted in truncated variants
that were unable to assist dimeric lipases in the maturation process [2,3]. Additionally, co-
immunoprecipitation studies performed on C-terminal LMF1 truncations showed that loop C
is important for interaction with dimeric lipases [10]. Before this current study, nothing was
known about the role, if any, of the N-terminal portions of LMF1.
Here, we determine which of LMF1’s domains are essential for its function and how LMF1
interacts with LPL by measuring the cellular levels of both proteins. To determine if the C-
terminal portions of LMF1 were sufficient to promote dimeric lipase maturation, we made
N-terminal LMF1 truncation variants. These LMF1 truncations are properly localized and
oriented in the ER membrane. However, expression of these constructs in cld/cld cells show
that the entire LMF1 protein is required for maturation of LPL. We generated a high-
affinity, polyclonal antibody using purified LMF1. We found that endogenous LMF1 levels
are low, and each LMF1 molecule promotes the maturation of at least 50 molecules of LPL.
Experimental Procedures
Expression constructs
Constructs for the expression of CD3δ-YFP and CFP-CD3δ [11] and mCherry-KDEL
(mCh-KDEL) [12] have been described. The coding sequence of human LPL was amplified
from pCMV-SPORT6-LPL (Open Biosystems) with a C-terminal V5 epitope tag and
inserted into the NheI and XbaI sites of pIRES-EGFP (Addgene). For LMF1 variants, the
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cDNA for human LMF1 was obtained from Open Biosystems (ID 100062174) and inserted
into the BamHI/Xho1 sites of pcDNA5/FRT/TO with an 8x C-terminal polyhistidine tag.
The forward primer for TM3 (5′-tcccggattgtcctgtggggc-3′) and TM5 (5′-
tcccggattgtcctgtggggc-3′) were selected based on computational models for the topology of
human LMF1 [10]. Both LMF1 truncations included an N-terminal MHRRRS ER retention
signal from human invariant chain isoform Iip33 [13] and an 8x C-terminal polyhistidine
tag. To generate pFastbacLMF1, the human LMF1 coding sequence was amplified with a C-
terminal His-tag and inserted into the Spe1 and Xba1 sites of pFastbac1 (Invitrogen).
Cell lines, transfection, and media collection
COS-7, cld/cld and cld/wt [14] cell lines were maintained in Dubelcco’s modified Eagle’s
medium, 10% fetal bovine serum, 1% penicillin/streptomycin, and 1% L-glutamine
(complete medium). Transfections were performed with 2 μg of DNA and X-treme gene
(Roche) according to manufacturer’s instructions. COS-7 cells were transfected using
Fugene 6 (Promega) with 0.3 μg of mCh-KDEL, 1.7 μg of LMF1 constructs, and 1 μg of
CD3δ-YFP and CFP-CD3δ. Cells were transfected at 80% confluency and harvested 24 h
post-transfection. For secretion experiments, 24 hours after transfection, the media of cld/cld
or cld/wt cells was changed to complete media but with 1% FBS and 15 u/mL of heparin 3
hours prior collection, 600 μL media was used per 9.5 cm2 well.
Western blot analysis
Cells were lysed 24 hours after transfection using lysis buffer (150 mM NaCl, 1% Triton
X-100, 50 mM Tris pH 8). The pellets were re-suspended with 3X SDS loading dye diluted
with 8M urea. Media, lysate, and pellet samples were separated using 12% SDS-PAGE.
Proteins were transferred to PVDF (Millipore) and blocked with 5% nonfat milk in TBS-T.
For LMF1 Westerns, chicken anti-LMF1 antibody was used at 1:10,000, AP-conjugated
anti-chicken (Thermo Scientific) was used at 1:5000, and Westerns were developed using
ECF reagent (GE Healthcare). Epitope tags were detected with anti-His and anti-V5
antibodies diluted 1:5000 (both mouse, Thermo Scientific). Mouse anti-GAPDH (Millipore)
was used at 1:20,000, and HRP-conjugated anti-mouse (Southern Biotech) was used at
1;20,000. Rabbit anti-progesterone receptor (PR, Santa Cruz) was used at a 1:100 dilution.
HRP-conjugated secondary antibodies were used at 1:5000. Westerns were developed using
ADVANSTA WesternBright reagent (Bioexpress).
Indirect Immunofluorescence
COS-7 cells were plated to 70% confluency on glass coverslips. Twenty-four hours post-
transfection, the cells were fixed with 4% paraformaldehyde in PBS for 15 min. Cells were
washed three times with PBS then incubated for 10 min with 0.1% triton X-100 and 100
mM glycine. Coverslips were washed three times with PBS, then blocked with 2% BSA for
30 minutes, and incubate with anti-His antibody (1:200 in 2% BSA) for 1 hour at room
temperature. Secondary antibody (Alexa Fluor 488-conjugated anti-mouse, Molecular
Probe) was diluted 1:800 in 2% BSA and incubated for 1 hour at room temperature in
darkness. DAPI (Sigma-Aldrich) was used at 0.8 μg/mL for 10 minutes. After further
washing in PBS, coverslips with cells were mounted facedown onto glass slides (Fisher)
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using ProLong Gold Antifade (Molecular Probes). Cells were examined at room temperature
under a Zeiss LSM 710 confocal microscope with a 63X oil/1.4 Plan Apo.
Protease protection assay (PPA)
The PPA was performed as described [15] with the following modifications. COS-7 cells
were permeabilized with 120 μM digitonin (Sigma Aldrich) for 1 min followed by 20 μM
trypsin (Sigma Aldrich) incubation for 2 min. Complete medium was added to stop trypsin
cleavage. The cells were spun at 9000 RPM for 5 minutes, washed with PBS, and lysed with
lysis buffer for 30 minutes. Samples were analyzed by Western blotting as above. LMF1 and
GFP were detected with anti-His and anti-GFP (rabbit, Abcam) antibodies, respectively, at
1:5000. HRP-conjugated secondary antibodies were used at 1:20,000.
Protein purification
LPL-V5 was purified essentially as previously described [16]. LMF1 was expressed in SF9
cells. Bacmids generated as per manufacture’s instructions (Invitrogen) were transfected into
SF9 cells using Xtreme gene (Roche). Baculovirus was amplified for three passages and
used to infect SF9 cells. Infected cells were harvested after 72 hours, resuspended in Buffer
1 (20 mM Tris pH 7.5, 100 mM NaCl, and 5 mM β-mercaptoethanol) with complete
protease inhibitor (Roche). Cells were lysed with 2 passes through an EmulsiFlex (Avestin).
Lysate was spun at 100,000 xg for 1 hour. The pellet was resuspended in Buffer 1 and
dounced until in solution. Fos-Choline 12 was added to 20 mM, the solution was rocked
overnight at 4°C and then spun at 100,000 xg for 1 hour. The supernatant was load onto Ni-
NTA (Qiagen), washed with Buffer 1 plus 3 mM Fos-Choline 12, and eluted in the same
buffer plus 400 mM imidazole. Protein-containing fractions were loaded onto a MonoS
column in Buffer 1 plus 3 mM Fos-Choline 12 and eluted over 15 column volumes to Buffer
2 (20 mM Tris pH 7.5, 1M NaCl, 1 mM DTT, 3 mM Fos-Choline 12). Select fractions were
further separated on S200 in Buffer 3 (20 mM Tris pH 7.5, 100 mM NaCl, 1 mM DTT, 3
mM Fos-Choline 12, 10% glycerol). Protein was flash frozen.
Antibody production
Antibodies against purified LMF1 were raised in chickens according to standard protocol
(Covance) and purified as described [17].
Genomic PCR
DNA was isolated from cld cell lines with DNeasy kit (Quiagen) according to manufactures
directions. The primer sequences used to distinguish between WT LMF1 and cld LMF1
have been described [2].
Results
The C-terminus of LMF1 is not sufficient for dimeric lipase maturation
The C-terminal, ER resident domain of LMF1 is necessary for efficient exit of LPL from the
ER, but the role of the N-terminal domain is unknown [2,3]. To identify the minimal LMF1
construct that can support LPL maturation, we made two N-terminal truncations of LMF1
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(Fig. 1A). To ensure that these truncation variants were properly targeted to and retained in
the ER, we added a short, N-terminal motif from the human invariant chain isoform Iip33
previously shown to target a plasma membrane protein to the ER [13]. This Iip33 segment
replaced N-terminal portions of LMF1 in two truncation constructs named TM3 and TM5
(Fig. 1A). TM5 is comprised of only the C-terminal ER domain whereas TM3 has this
domain plus loop C, which was shown to be important for binding to LPL [10]. These
truncations allowed us to test the role of loop C and the C-terminus of LMF1 independently.
Full length (FL) LMF1, TM3 and TM5 all have C-terminal His tags for uniform detection,
and all were transiently transfected in cld/cld cells. Membrane fractions from these cells
were analyzed by Western blot for LMF1. The FL, TM3, and TM5 LMF1 variants were
detected at the expected masses of 60, 43, and 27 kDa (Fig. 1B). TM5 was highly expressed
and so 5-fold less protein was loaded to allow detection of the other LMF1 variants. No
LMF1 was detected in the soluble fraction, showing that the truncation versions localize to
the membrane.
Next, C-terminally V5-tagged LPL was co-expressed with each of the three LMF1
constructs in cld/cld cells to determine the minimal domain of LMF1 sufficient for LPL
maturation. Heparin was added to the media to induce release of LPL from the cell surface
into the media. LPL is expressed in cells with all LMF1 constructs, as it is detected in the
lysate and pellet fractions (Fig. 1C). However, LPL is only secreted when FL LMF1 is
present (Fig. 1C, media fraction). Taking into account that only 1/5th of the TM5 pellet was
loaded, there is more LPL in the pellets of TM3 and TM5 than in the FL LMF1 pellet
fraction. This suggests that when FL LMF1 is not present, LPL can’t fold properly and is not
able to exit the ER, as shown for cells lacking LMF1 [18]. Taken together, the release of
LPL into the media only with FL LMF1 and the accumulation of LPL in the pellets when
co-expressed with the TM3 and TM5 truncations indicate that FL LMF1 is needed for the
maturation process of LPL.
Localization of LMF1 constructs by fluorescence microscopy
To ensure that the N-terminal ER retention signal from Iip33 properly targeted both LMF1
truncation variants to the ER we tested for co-localization with an ER marker (mCh-KDEL)
by immunofluorescence. COS-7 cells were co-transfected with LMF1, TM3, or TM5 and
mCh-KDEL. Figure 2 shows that LMF1 co-localizes with mCh-KDEL. The merge of the
two bottom panels of Fig. 2 shows that both LMF1 truncation variants co-localize with
mCh-KDEL as well as FL LMF1 does. We conclude that although TM3 and TM5 are not
sufficient to promote LPL maturation, both truncations are present in the ER.
Membrane topology of LMF1 constructs
Truncation of the N-terminus of LMF1 could result in insertion of the protein into the ER
with an incorrect orientation. We performed a protease protection assay (PPA) to determine
the orientation of the LMF1 truncations in the ER. In this assay, the plasma membrane is
selectively permeablized with digitonin followed by trypsin treatment [15]. Trypsin cleaves
membrane domains not protected within the lumen of organelles. COS-7 cells transfected
with CD3δ-YFP (CD3δ with a YFP tag exposed to the cytosol) served as a positive control
for trypsin cleavage (Fig. 3A, left panel). CD3δ with a CFP tag protected by the ER lumen
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(CFP-CD3δ) was a negative control to ensure that the organelles were preserved at the
digitonin conditions used. Figure 3A shows complete loss of CD3δ-YFP signal within 2
minutes of trypsin exposure whereas incubation with digitonin alone does not result in YFP
degradation. The right panel of Figure 3A shows no degradation of the 50 kDa CFP-CD3δ
band, confirming that the assay conditions leave the ER membrane intact.
We next tested if FL, TM3 and TM5 LMF1 were properly oriented in the ER. If these
proteins have the correct topology, their C-terminal His-tags will be trypsin resistant. Unlike
CFP-CD3δ, which has ER-protected CFP attached to a single transmembrane domain,
LMF1 should show some cleavage products after trypsin treatment. Human LMF1 has 5
transmembrane domains with 16 cytosolic trypsin cleavage sites (PeptideCutter). Trypsin
could cut LMF1 multiple times but only the products with a C-terminal His-tag will be
detected. Following trypsin addition to cells expressing FL LMF1, we detect bands
corresponding to both the full protein (60 kDa) and cleavage products. The cleavage
products, ranging from 27 to 20 kDa, are likely due to the 7 trypsin sites in loop D of LMF1
(Fig. 3B, left panel). After trypsin treatment uncleaved TM3 was present at 43 kDa in
addition to lower molecular weight cleavage products (Fig. 3B, middle panel). For TM5
(Fig. 3B, right panel); uncleaved TM5 appears at about 27 kDa. The band profile is not
altered upon trypsin addition because no exposed cytosolic loops are expected in this
construct. Retention of the majority of the signal from the His-tag following trypsin
treatment indicates that TM3 and TM5 have their C-termini located in the ER. Thus, the
Iip33 ER retention signal targets the LMF1 truncation constructs to the ER with the same
membrane orientation as WT LMF1.
Low level LMF1 expression is sufficient for LPL secretion
The relative expression levels of LMF1 mRNA have been compared in different tissues, but
little is known about LMF1 protein levels [2]. We generated an antibody against LMF1 to
measure its cellular levels. LMF1 was expressed in SF9 cells and purified to homogeneity as
shown by coomassie staining and gel filtration (Fig. 4A). Purified protein was used to raise
antibodies against LMF1 in chickens. This antibody could detect as little as 17.5 fmoles of
purified LMF1 (Fig. 4B). However, Western blots using this antibody failed to detect a
specific band for LMF1 in the cld/wt vs. cld/cld cells (Fig. 4B). When we transfected a
plasmid expressing LMF1 into the cells, we observed a band at the expected molecular
weight of LMF1 (Fig. 4B).
Because we could not detect endogenous LMF1 in cld/wt cells, we wanted to ensure that
both cell lines had the expected genotype. We confirmed the correct genotype of these cells
by analysis of the genomic DNA. Genomic DNA was harvested and tested by PCR for
insertion of the murine endogenous retrovirus into intron 7 of LMF1, which defines the cld
mutation (Fig. 4C) [2]. PCR products of the expected size were observed (Fig. 4C)
indicating that a WT copy of LMF1 is present in the cld/wt but not the cld/cld cells, as
expected.
We cannot report the exact number of LMF1 molecules per cell, but can calculate an upper
limit. The assays in Figure 4B used 1 × 104 cells. Additionally, the membrane fraction of a
greater number (1 × 106) of cld/cld and cld/wt cells was harvested, solubilized, and probed
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for LMF1 (data not shown). Based on these cell counts and the detection limit of our
antibody, we can conclude that there are less than 10,000 molecules of LMF1 per cell, a
relatively low expression level. A proteomic analysis of mammalian cells indicates that
approximately 75% of proteins are expressed at higher levels [19]. Indeed, LMF2 was
identified in this analysis, but LMF1 wasn’t [19]. We next quantified the amount of LPL-V5
secreted from transiently transfected cld/wt cells into fresh media three hours after heparin
addition (Fig. 4D). Purified LPL-V5 served as a standard for quantification. These
experiments revealed that on average, 500,000 molecules of LPL were secreted/cell. Thus,
each molecule of LMF1 can promote the maturation of at least 50 molecules of LPL.
Discussion
Previous studies on LMF1 have focused on the C-terminus. In patients with defective
LMF1, mutations are located in the C-terminus and in vivo co-IP’s show that loop C of
LMF1 binds to LPL [2,3,10]. Based on these findings, we hypothesized that LMF1’s C-
terminus is not sufficient for the maturation of dimeric lipases but the C-terminus in
combination with loop C would promote lipase maturation. To test this hypothesis, we made
truncations of LMF1 starting from the N-terminus. Because LPL must be properly folded to
enter the secretory pathway [8], we tested LPL secretion into the media in cells expressing
only the truncated variants of LMF1. These data indicate that FL LMF1 is required for the
maturation process of LPL. Because the ER retention signal of LMF1 is not known, we used
the ER retention signal of Iip33 to ensure ER localization of the truncated variants. To
demonstrate that the TM3 and TM5 LMF1 truncations did not compromise ER localization
and the luminal orientation of the C-terminus, we co-localized LMF1 with an ER marker
and performed a protease protection assay. The results of these combined experiments
demonstrate that TM3 and TM5 LMF1 have the same localization and topology as FL
LMF1. However, they cannot promote the maturation of LPL, indicating that the N-terminus
has an important, but unknown function.
We generated a polyclonal antibody to measure LMF1 protein levels. Although this
antibody was very sensitive it could not detect endogenous levels of LMF1. We calculated
that there are at most 10,000 molecules of LMF1 per cell, and that each molecule of LMF1
assisted in the maturation of at least 50 molecules of LPL. These data hint at LMF1
function. LMF1 protein is present at low levels compared to general chaperones like GRP78,
Calnexin, and Calreticulin, which are present at over 1,000,000 molecules per cell [19]. It
thus performs a specialized maturation function that will be the focus of future research.
It is widely accepted that LMF1 is required for the maturation of dimeric lipases, but it is not
known if LMF1 coordinates the activities of other interacting partners. FL LMF1 is required
for lipase maturation, but only loop C and the C-terminus have a known role. This suggests
that other domains of LMF1 could interact with binding partners required for lipase
maturation. Supporting this idea, we were unable to detect a strong, direct interaction
between purified LPL and LMF1 in vitro (data not shown). Additionally, real time-PCR
analysis shows that LMF1 mRNA is expressed at higher levels in tissues that lack dimeric
lipases compared to tissues expressing dimeric lipases [2]. Future studies will be needed to
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determine if LMF1 requires interacting partners to promote lipase maturation as well as if
LMF1 has a role other than lipase maturation in other tissues.
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• N-terminal truncations of LMF1 are properly localized and oriented in the ER.
• LMF1’s N-terminus is important, as the truncations don’t promote LPL
maturation.
• LMF1 is expressed at low levels relative to general chaperones.
• Each molecule of LMF1 promotes the maturation of multiple molecules of LPL.
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The N-terminal domain of LMF1 contributes to LPL maturation. A. A schematic of LMF1’s
topology. B. Western blots against the C-terminal His tag show that FL, TM3 and TM5
truncations are associated with the pellet fraction. Loading controls include GAPDH for
soluble proteins in the lysate fraction and PR for membrane proteins. C. Western blots of the
media fraction show that LPL-V5 is secreted in cld/cld cells co-expressing the FL, but not
the TM3 or TM5, LMF1 constructs. Arrows indicate expression of LPL-V5. Although we
loaded 1/5 as much of the highly expressed TM5 construct in all panels to allow detection of
other constructs, saturated pixels were unavoidable in panel 5.
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LMF1 truncation variants localize to the ER. Immunocytochemistry of the LMF1 variants
(green) was compared to the ER marker mCh-KDEL (red) in COS-7 cells. All LMF1
constructs show perinuclear staining characteristic of the ER as is confirmed by co-
localization with mCh-KDEL. Scale bars represent 20 μm.
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Topology of LMF1 truncations. A. CD3δ-YFP and CFP-CD3δ were used as positive and
negative controls for trypsin cleavage, respectively. The middle and right panels show the
Western blots for expression and the PPA. Lane 1 was mock (M) transfected, lane 2 shows
untreated cells (UT), lane 3 has digitonin (D) addition for 3 minutes, and lane 4 has trypsin
(T) for 2 minutes (after a 1 minute incubation with digitonin). Arrows indicate the FL
version of each construct. B. Expression and PPA for WT LMF1 and the two truncation
constructs. Lanes are labeled as in A.
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LMF1 purification and cellular levels. A. Gel filtration trace of purified LMF1 with a
coomassie stained gel. B. Western blot showing that α-LMF1 antibody can detect as little as
17.5 fmole of purified LMF1. Cells are mock transfected (M) or transfected with a plasmid
expressing LMF1. PR is a loading control for the pellet fraction. Arrows indicate both PR
isoforms. C. The diagram at the top indicates the oligos (D, E, F) used to test for the
insertion of the murine endogenous retrovirus into intron 7 of LMF1. PCR products, below,
show that cld/wt and cld/cld cells have the expected genotype. D. Western blot for
quantification of LPL-V5 released from cld/wt cells. S1 and S2 indicate two replicate media
collections.
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